Novartis’ RemIND trial of oral remibrutinib meets primary endpoint

The trial is assessing remibrutinib's safety, tolerability and efficacy in adults with CIndU unresponsive to H1-antihistamines. Novartis has reported that its pivotal Phase III RemIND trial, evaluating oral remibrutinib in chronic inducible urticaria (CIndU), achieved the primary endpoint.

The study met this endpoint for the three most prevalent CIndU types: cold urticaria, cholinergic urticaria, and symptomatic dermographism, with notably higher complete response rates compared to placebo at week 12.

The randomised, global, multi-centre, placebo-controlled, double-blind, parallel-group Phase III trial is assessing the safety, tolerability and efficacy of remibrutinib in adults with CIndU who have not responded adequately to H1-antihistamines. Its main outcome measured was the proportion of complete responders at week 12, evaluated through provocation tests for each of the three CIndU subtypes.

Novartis has filed a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) for remibrutinib in symptomatic dermographism.

The company plans to submit the full dataset to global health authorities in the coming months and to present RemIND findings at upcoming medical congresses. Novartis immunology development global head Angelika Jahreis said: “The positive RemIND trial results across three different types of CIndU underscore the potential of oral remibrutinib to achieve complete symptom relief for people living with CIndU and build on its recent FDA approval in chronic spontaneous urticaria (CSU).

“Today’s findings reinforce that remibrutinib could be the first targeted therapy to improve spontaneous and inducible forms of chronic urticaria, helping address a major gap in care for people living with these conditions.”

Remibrutinib is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor that blocks the pathway responsible for histamine release.

By limiting the release of histamine, it helps to reduce symptoms like hives and swelling linked to CIndU. In China and the US, remibrutinib received approval for adult CSU patients who do not respond to H1-antihistamines.

The therapy is under further investigation for other immune-mediated conditions, including food allergy and hidradenitis suppurativa, as well as neuroscience indications.

Earlier this week, Novartis announced final data from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slowed kidney function decline in adults with immunoglobulin A nephropathy (IgAN).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!